Lilly And Innovent’s Rituximab Gets Chinese Nod

Companies Continue To Collaborate On Oncology Biologics

 
• By Akriti Seth

Eli Lilly and Chinese biotech specialist Innovent Biologics have received approval in China for their biosimilar rituximab, Halpryza. The companies are continuing to co-develop and commercialize other oncology medicines for the Chinese market.

China - syringe
Eli Lilly and Innovent have partnered on rituximab injection in China • Source: Shutterstock

More from Biosimilars

More from Products